Advancing Alzheimer’s Disease Care: Convenience for both Patients and Families with Oral Blarcamesine with Long-term Time Saved - Join Clinical Trial NCTNCT03790709
How to Join This Clinical Trial - NCTNCT03790709
Learn how to participate in this PHASE2, PHASE3 trial studying Blarcamesine (ANAVEX®2-73) for Alzheimer’s disease, early-stage Alzheimer’s disease, ABCLEAR32 population (wild-type SIGMAR1 and COL24A1 genes). Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Alzheimer’s disease, early-stage Alzheimer’s disease, ABCLEAR32 population (wild-type SIGMAR1 and COL24A1 genes). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Alzheimer’s disease, early-stage Alzheimer’s disease, ABCLEAR32 population (wild-type SIGMAR1 and COL24A1 genes)
- Treatment Being Tested
- Blarcamesine (ANAVEX®2-73)
- Study Phase
- PHASE2, PHASE3 - Large-scale efficacy study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT03790709 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at multiple locations. Find a study site near you:
How to Enroll in This Study
To learn more about participating in this PHASE2, PHASE3 clinical trial for Alzheimer’s disease, early-stage Alzheimer’s disease, ABCLEAR32 population (wild-type SIGMAR1 and COL24A1 genes):
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai as Your Clinical Trial Matching Service
Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:
- Find clinical trials that match your condition
- Get matched to the right study location near you
- Connect directly with study coordinators
- Understand if you qualify with simplified eligibility screening
- Navigate the enrollment process with personalized support
- Access new treatments through clinical research participation